Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Exact Sciences (EXAS) upgraded to Buy from Neutral at Goldman Sachs by analyst Patrick Donnelly, who said the current momentum of the Cologuard commercial ramp provides "strong basis" for the company's premium valuation while the combination of positive Cologuard catalysts and new product roll-outs provide upside to current levels, even after the stock's 75% rally since the beginning of 2018. Exact Sciences is a "must-own growth stock" given the "clean runway forward that is largely in its control with potential for discovery value in the pipeline outside of Cologuard," the analyst said. 2. Siemens (SIEGY) upgraded to Overweight from Neutral at JPMorgan by analyst Andreas Willi, who sees a relative valuation opportunity after the stock's 27% underperformance over the past two years. He believes investor sentiment can improve "after a period where the story has drifted." 3. Kadmon (KDMN) upgraded to Buy from Neutral at Citi by analyst Robyn Karnauskas, who assigned a 50% probability to KD-025 in chronic graft versus host disease with an unadjusted ~$900M market opportunity. However, upside to the stock will depend on quality of the data likely, Karnauskas said. 4. EverQuote (EVER) upgraded to Buy following Q4 beat at BofA/Merrill by analyst Mat Schindler, who said user growth has re-accelerated, supporting evidence of a turnaround, and thinks estimates are conservative and views the risk/reward as attractive. 5. Ally Financial (ALLY) upgraded to Buy from Hold at Sandler O'Neill by analyst Christopher Donat, who said he believes Ally's near-prime auto finance book is "meaningfully less risky" than Santander Consumer's (SC) book or the unsecured credit cards of Discover (DFS) and Capital One (COF), yet all four stocks trade at similar multiples. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage,
click here.